← 返回

缺氧生产条件下功能性 CD19 CAR-T 细胞的制备

英文原题:Production of functional CD19 CAR T cells under hypoxic manufacturing conditions.

查看英文原题

Production of functional CD19 CAR T cells under hypoxic manufacturing conditions.

PubMed 2025/10/08(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们证明,在 2% O₂条件下生产并无不利影响,反而赋予 CAR-T 细胞细微但持久的功能和表型变化,这值得进一步研究低氧生产对低氧肿瘤微环境中 CAR-T 细胞功能性的影响。

中文摘要

研究者对来自健康供者或CLL患者、分别在21%氧气(常氧CAR)或2%氧气(低氧CAR)条件下生产的CD19靶向CAR-T 细胞,进行了体外表型和功能评估。

在2%氧气下生产健康供者来源CAR-T 细胞,促进了幼稚样亚群富集。低氧CAR与常氧CAR细胞功能不同:低氧CAR的CD4+细胞较常氧CAR的CD4+细胞产生更多IL-2和肿瘤坏死因子。2%氧气下生产并未损害细胞存活或受到相应抗原刺激后的增殖,且增强了细胞活化。经低氧环境长期刺激后,低氧CAR产品仍富含幼稚样细胞,并保留细胞毒性和细胞因子产生能力。对于CLL患者来源CAR-T 细胞,常氧CAR与低氧CAR亚群的功能和表型相近,但线粒体代谢不同。讨论:研究显示,在2%氧气下生产CAR-T 细胞并无不利影响,反而会带来细微但持久的功能和表型改变,值得进一步研究低氧条件生产对CAR-T 细胞在缺氧肿瘤微环境中功能的影响。

展开英文摘要原文

We performed in vitro phenotypic and functional assessments of CD19-directed CAR T cells produced in either 21% ( Nor CAR) or 2% ( Hyp CAR) O 2 derived from healthy donors (HDs) or patients with CLL.

Production of HD-derived CAR T cells in 2% O 2 promoted the enrichment of a na ve-like subset. Hyp CAR and Nor CAR cells were functionally distinct; CD4+ Hyp CAR cells produced more IL-2 and tumor necrosis factor than CD4+ Nor CAR cells. Production in 2% O 2 was not detrimental to viability or proliferation upon cognate antigen-stimulation and led to increased activation. After chronic stimulation in hypoxia, Hyp CAR-product remained enriched in na ve-like cells, and demonstrated cytotoxic and cytokine production capacity. In CAR T cells derived from patients with CLL, Nor CAR and Hyp CAR subsets were functionally and phenotypically comparable, but displayed different mitochondrial metabolism. DISCUSSION: We demonstrated that production in 2% O 2 is not detrimental, confers subtle but lasting functional and phenotypic changes in CAR T cells warranting further research on the impact of hypoxic production on CAR T cell functionality in hypoxic tumor microenvironments.

论文信息

作者
Micallef Nilsson I、Poiret T、Ryu J、Mohammadpour M、Henriksson J、Österborg A、Mattsson J、Schurich A
单位
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.Sweden
期刊
Frontiers in immunology2025
原文标识
PubMed 41132651 · DOI 10.3389/fimmu.2025.1675786